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Chapter 1
Pain in Society
Introduction

Although chronic pain in the United States is well recognized, it is often undertreated and under-diagnosed for a variety of reasons. My experiences with patients who
have chronic pain lead to the formulation of the main themes of this thesis. It has been

my experience for the last seven years, that people with chronic pain are seeing numerous

providers, receiving numerous medications, and are remaining in pain, ultimately

becoming frustrated with the medical system and physicians in general. While I was
attending classes for my public health degree, I realized that chronic pain, as a major
public health issue, is not addressed adequately, nor is it given appropriate attemion in
our medical schools and residency programs. These doctors in training are not

adequately prepared for their future careers and the treatment of chronic pain.
This manuscript will tie together many aspects of chronic pain, it’s causes,

diagnosis and management, which I believe are affecting appropriate treatment strategies.

I will also show that physicians have grown to fear using narcotics because of legal issues
and state regulations, which attempt to decrease the illicit use of controlled substances.

These regulations are adversely affecting chronic pain management. In addition, I will
demonstrate how the lack of education of our young physicians is contributing to the

inadequate treatment of pain, and will directly link this to the reservations older
physicians have in prescribing comrolled substances. Finally, I will show how the
understanding of the pathophysiology of chronic pain can influence pain management. It

is through research focused on the specific mechanisms and physiologic changes that

develop when painful stimuli are ever present.
The resources utilized for preparing this manuscript come from personal

experience, interviews with other physicians treating pain, and literature searches for
chronic pain. The literature searches focused on pathophysiology, diagnostic and

treatment strategies, public health issues, law documents, and current Federal, State and

local regulatory documents. In addition, the Internet was utilized to reference common
materials available to the public relating to pain, its diagnosis, and treatment. Finally,
numerous textbooks and primary literature were used to support the current knowledge

base of the pathophysiology and biology of chronic pain, how it differs from acute pain,
and how medications such as the opiates affect the pain sensing pathways in human

beings.

Human Rights

Every person has the right to health. This is not a legal right but rather a human
right. Although in the United States we have developed a medical system that grants the
most access to medical care to privileged individuals, we are continually faced with the
awesome task of providing care to those who are not privileged. Health is a fundamental

human right, which it is the requisite entitlement for all other human rights. Every
human being is entitled to maintain the highest possible standard of health that is
conducive to living a life in dignity [ 1 ]. Internationally, pain is recognized as an

impediment to health and dignity. Alleviating pain and helping to maintain dignity,
especially during the terminal phases of illness, is recognized as a necessity 1 ].

Understanding this and knowing that it is proper to help relieve pain, it is hard to

understand why more of an emphasis is not placed on the education of our medical
students and residents in training regarding pain and its management.

Americans with Pain

In the United States the treatment of pain creates anxiety and frustration among
physicians. The usual and customary approaches to managing low back pain, for
instance, have proven themselves to be limited at best and debilitating at worst. Surgeries

and surgical techniques have developed and have been refined over the years but are not
the solution for all patients and often leads to additional pain due to altered mechanics

[2,3]. With its many causes, the management of pain has been a nuisance to physicians
because of the relatively limited tools, medicines, therapies and treatments available.

Over 75 million Americans suffer serious pain on a yearly basis. Of those in
serious pain, annually 50 million endure serious chronic pain lasting 6 months or more

[4]. Headache, low back pain, arthritis and other joint pain, and peripheral neuropathy
are the most common forms of chronic pain and are the most common presenting

complaints in a physician’s office [5]. Over 26 million adults experience frequent back

pain and 2/3 of Americans will have back pain during their lifetime [6]. In the United

States, 1 out of every 6 Americans suffers from arthritis [7].
Chronic pain has been recognized as a public health issue. A recent survey to see

just who was stricken with chronic pain in the United States was performed and it was
found that there was an increased burden of unrelieved pain in children, the elderly,

minorities, and patients with active addiction or history of substance abuse, those with

developmental disabilities, and those with serious chronic diseases [8]. Of those
experiencing pain, 61% are women and the majority of these people were 51 years of age
or older. Seventy-two percent of American’s surveyed stated they have had pain for
more than 3 years, which includes 34% who have had chronic pain for over 10 years.

Seventy-six percent of people with chronic pain experience their pain daily. A staggering
48% of those who experienced pain daily say this pain is ever present. Fifty-nine percent

of those patients with ever-present chronic pain say their pain is not under control [8].

Chronic Pain Impact on the Individual
Chronic pain impacts many aspects of a person’s life. Fifty-one percent of

employed people who have pain, state that it adversely affects their productivity at work.

Forty-one percent of these patients are unable to complete a full day’s work. This
translates into lost productivity and increased expense for industry in the United States.

In addition to lost productivity, 45% of those in chronic pain state their personal
relationships suffer due to their condition. These relationships are with a spouse or

partner, a child or grandchildren, or even with a close friend [8].

Quality of Life Impact

More than 50% of people in chronic pain are unable to perform normal activities
of daily living. Seventy-five percent of people in pain state that their chronic pain

impacts their sleep and their ability to play sports or exercise [8]. This has particular
impact on younger patients with chronic pain in that the ensuing de-conditioning of the

musculoskeletal system puts them at risk for developing new and more extensive pain
issues.

As stated above, chronic pain impacts women more than it does men. Seventythree percent of women with pain state that it prevents them from doing household

chores, as compared to 57% of men who state their household chores are affected. In
addition, the emotional state of women is affected more than men with chronic pain.

Seventy percent of women develop stress and 55% lose desire and motivation to perform
activities of daily living, or pleasurable events. Thirty-nine percent have decreased

coping ability, and 36% have decreased desire for sexual relationships [AA].

As you will see below, chronic pain does not affect adults only; there is now a
new generation of children and adolescence who are affected by chronic pain. This will

lead to an emerging pandemic when these individuals enter adulthood.

Pain Has Many Faces

There are many forms of chronic pain. Often the initial event that triggered the

pain is remote and does not affect the course of treatment since the pain takes on a

pathophysiologic process of its own. Chronic, non-malignant pain can develop from pain
generating structures such as the musculoskeletal system, the neurologic system, or it can
be idiopathic. Neuropathic pain can be central or peripheral depending on the site of

injury causing the pain. Neurologic insults such as post-herpetic neuralgia or diabetic

peripheral neuropathy can generate unremitting severe pain in the periphery while central
neuropathic pain follows a central ischemic event in the brain [9].

Myofascial Pain syndromes are another major cause of chronic pain.

Fibromyalgia is a generalized myofascial pain syndrome that is widespread and can be

debilitating [9]. So unique is this syndrome that it is described in the literature as its own
entity and is no longer considered a subset of myofascial pain syndromes [9]. Although

the exact mechanism is not known, fibromyalgia is the subject of intense research and
novel therapies. The hallmark of fibromyalgia is generalized allodynia (a condition in
which ordinary, non-painful stimuli evoke pain) and hyperesthesia (a condition in which

the body is much more sensitive than normal to stimulation). These characteristics tend
to be the focus of therapeutic interventions [9]. Other myofascial pain syndromes can.
cause significant morbidity and often result from acute injury and repetitive motion

strains [10].

All of these forms of pain are the subject of a large body of research and are
adding to the knowledge base of pain medicine. One thing is certain; chronic pain can
cause a significant amount of morbidity and mortality, which in and of itself is a public

health concern [ 11 ].

Musculoskeletal Pain
Musculoskeletal problems can often lead to impairment or disability and weighs

heavily on public health support systems. Often, an acute musculoskeletal injury
commands immediate attemion by a physician but it may be under-treated because both
the physician and the patient are driven simply to decrease pain and inflammation, and
not to address the underlying injury directly [ 12]. This approach indeed decreases the

pain, but can also lead to early discontinuation of any therapy and thus incomplete

healing. When the drugs of choice are non-steroidal anti-inflammatory drugs (NSAIDs),
the necessary inflammatory response needed to generate the repairative tissues is

blocked. This can lead to re-injury and ultimately to increased pain. Arthritis pain is a
prime example of this theory. When an arthritic knee is overused, it develops an

inflammatory response. In the uncontrolled setting, this inflammation leads to a degree
of disability. When anti-inflammatory medications are administered to the patient

chronically, the inflammation decreases, but so does the healing potential of the knee.
Arthritis is progressive and there are many factors leading to the development of this

condition, but the acceleration and worsening of the arthritis is often driven by the
medications used to decrease inflammation (Figure 1).

Figure 1.
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All ages are affected by pain. Teens and young adults are increasingly developing

back, neck and shoulder pain. Prior to the 1980s, teens and young adults were not
thought to be a major risk group for developing musculoskeletal pain. However, in a
survey done in Finland in the 1980s, it was discovered that chronic back and/or neck pain
was common among teens [13]. In fact, a Finnish population survey in 1991 found 15%

of 12-18 year olds had pain in the neck or shoulder at least once a week, and 8% had pain

in the lower back [14]. Also, among Finnish 10-12 year olds, about 30% had

musculoskeletal pain at least weekly 15]. It is more prevalent in girls than in boys and
affects older groups of teens more commonly [15]. More recently, the use of backpacks

by adolescents in the United States suggests that a major cause of this increase in
musculoskeletal pain may be due to increased loads school-age adolescents are asked to
carry 16].

Low back pain can be disabling among adults and often leads to economic loss
and financial strain on individuals and families 17]. The 1990’s saw a steady rise in the
number of people experiencing back, neck, and shoulder pain. By the end of this decade
there were more people with back and shoulder pain than in the preceding decade [15]. It
can be expected that there will be a surge in degenerative musculoskeletal pain and

disability in adults based on this information about teens and that this could represent a
new disease burden on our youth

[15].

Economic Impact

It is estimated that chronic pain, in it’s many forms, costs the United States
approximately $90.7 billion per year [18, 19]. This is very difficult to calculate because
of the many aspects of pain that will be discussed below. It is safe to say though, that the

largest portion of the pain price tag is the lost productivity and missed workdays
associated with pain. On average, people with back pain incur health care expenditures

60% higher than those individuals without back pain [19]. In addition, health care costs
were higher per-capita in those people with back pain who were older, female, white,

medically insured, or suffered from disc disorders [19].

A discussion about the public health ramifications of pain in its chronic state must
address some basic groundwork and science. This author believes there are two generally

accepted beliefs by physicians regarding pain treatment that interferes with the treatment
of chronic pain. First, that chronic pain is simply long standing acute pain, and second,
that chronic pain will respond to the same medications in the same way that acute pain
will respond. A logical corollary is that if the same medications can be used, and that if

the pain is simply long-standing acute pain, then prescribing medications would be long-

standing and thus, many physicians do not want to get involved.

As will be discussed, the pathophysiology of chronic pain is different from acute
pain. Based on this, it is reasonable to assume that the treatment of chronic pain must
have different requirements. The mis-treatment of chronic pain is multifaceted and

complex. But the basic reason is that a solid foundation is not laid in the early years of
medical training. Medical schools and residency training programs do not do a good job

in teaching students about pain and its treatmem [20]. Because recently technology has

been able to reach into the human body more deeply the understanding of chronic pain
has grown. However, even with this knowledge growth, the dogma of treating chronic

pain is slow to improve. In order to put this into perspective, we need to develop the
foundation on which pain treatment must develop.

Chapter 2
Basic Science
What is Pain

Acute pain plays a vital role in human survival. When acute, pain is a symptom
or warning that must be heeded less grave consequences could follow. In one sense, pain

is good and necessary as long as its presence is well defined with a beginning and an end.

When these well-defined borders are compromised and the pain producing insult is not

halted, pain becomes chronic, pathologic and, in some cases, debilitating. Chronic pain is
no longer merely a symptom of a pathologic process but rather a chronic disease state

thus mandating a change in diagnostic and treatment strategies [21]. There is no

physiologic role or survival advantage to having chronic pain and therefore the goals of

therapy must be aimed at the pain generating and maintaining process, not the remote
initiating event. Simply masking the symptoms of the chronic pain disease does not alter
its natural history and ultimately leads to treatment failure and dissatisfaction by both the

physician and patient.
Pain is an "unpleasant sensory and emotional experience associated with actual or

potential tissue damage, or described in terms of such damage" [22]. This description of
pain alludes to the vast nature of pain but also relates to the reader the emotional and
cognitive aspects of pain and its effect on people. Pain is very subjective and for each
individual the sensation of pain varies. When it is constant and chronic, the way pain is

perceived changes. It is a conscious experience that is influenced by somatosensory and
psychosocial factors. The perception can range from mild aches to complete disability
based on a combination of the influencing stresses, both physical and emotional, and their
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impact on the individual’s psychosocial foundation. Pain is transformed into the disease
and has a combination of physical, psychological, social, economic, and spiritual effects
on an individual [23].

Neurology of Pain
The sensation of pain travels via an incredibly sophisticated system of highly

specialized tissue. Humans have the most highly developed and complicated nervous
system in the animal kingdom. All bodily functions are under neurological control in one
way or another [24]. With its complexity comes difficulty in diagnosis especially when
different types of pain are present. Specialized nerve endings called primary afferent

nociceptors are present where the sensation of pain is critical for maintaining
homeostasis. In other words, the tissue that needs to be protected must have a sense

organ that is able to detect noxious stimuli and thus allow the individual to respond to
that stimulus. The most nociceptor rich tissue in the body is the skin since it is our most
intimate interface with our environmem; however, nociceptors are also found in

subcutaneous tissue, periosteum, joints, muscles and visceral tissue [25].

Nociceptors are peripheral and are the free nerve endings of a sensory neuron
with a cell body located in the dorsal root and trigeminal ganglia. When these receptors
are activated by a noxious stimulus an impulse is sent to the spinal cord or brainstem

nuclei predominantly via A-delta (myelinated and relatively fast) or C fibers

(unmyelinated and are the large majority of peripheral nociceptors) axons. Nociceptors
are depolarized by various stimuli--some by a specific type of stimulus such as high-

threshold mechanoreceptors, while others by more than one type of stimulus such as the
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polymodal nociceptor. In either case, this nociceptive information is then distributed to
various cortical and subcortical structures of the brain. The result: conscious perception

of pain and conscious and subconscious initiation of neuromodulatory, endocrine, and
emotional responses [25]. When discussing pain that is generated from the bone it is
critical to realize that the pain sensing organs of the bone are nociceptive afferent fibers

that are most concentrated in the periosteum [26]. The periosteum is often the main
source of pain caused by metastatic cancer, traumatic injury and even ligament or tendon

injury, to name a few.
Pain arising in muscles, tendons, ligaments, and bones is detected by the free
nerve endings imbedded in their connective tissue

[27]. Joints have four types of sensory

endings each of which are morphologically different and have unique physiologic

responsiveness [27]. These cells are within and around the capsule of the joint and are
responsible for detecting acceleration and deceleration. In addition, some of these cells
within the ligaments respond to strain and allow for inhibition as a protective mechanism

[28]. Finally, abundant in the synovial membrane, capsule and periarticular connective
tissue are free nerve endings which are believed to respond to potentially injurious

mechanical stresses and mediates pain in the diseased or traumatized joint [27]. Articular
innervation is so important that it is the focus of Hilton’s Law which states that every

peripheral nerve supplying a muscle sends a branch to the joint moved by that muscle and
to the skin overlying the joint [27]. So when a joint is the source of pain all of its

components, which are interconnected by their innervations, can generate pain to some

degree.
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Nociceptors fire in proportion to the amount of noxious stimuli they experience.
When pain is prolonged, repeated and intense, and in the presence of damaged tissue or

inflammation, the threshold for activating primary afferent nociceptors is lowered and the

frequency of nociceptor firing is increased with relatively less noxious stimuli [29]. This
process is called "sensitization" and is often mediated by bradykinin, some

prostaglandins and leukotrienes [29]. In fact, tissue that is typically non-reactive to
noxious stimuli can become intense sources of pain [29]. An important example of
sensitized tissue is when a constant irritating and noxious stimuli is present at the viscera.

The A-delta and C afferents that innervate the viscera are usually inactive and non-

responsive to stimuli, but when sensitized they respond pathologically and can become a
source of deep and debilitating pain

[29]. It is important to realize that patients with

chronic pain respond differently and with smaller amounts of stimuli, which often leads

those patients to display characteristic "pain behavior" in an attempt to be pain liberated

by physicians [30].
The main neurotransmitter used by nociceptors synapsing with the dorsal horn of

the spinal cord is glutamate. Glutamate can bind to several different classes of receptors
but plays a critical role in generating and maintaining chronic pain. Typically, the
sensation of acute pain is mediated through AMPA (alpha-amino-3-hydroxy-5-methyl-

isoxazole-4-propionic-acid) receptors. These are always exposed on afferem nerve
terminals. These receptors, however, are not the key players in chronic pain. In contrast,

the NMDA (N-methyl-D-aspartate) receptor is most involved in the sensation of chronic

pain. This receptor lays dormant unless there has been a persistent or massive release of

glutamate. Repeated activation of AMPA receptors dislodges magnesium ions that act
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like plugs in the transmembrane sodium and calcium channels of the NMDA receptor

[31 ]. This conformational change in the neuronal membrane makes these receptors
susceptible to stimulation and is the primary step in central hypersensitization and marks
the transition from acute to chronic pain [30,32].
Activation of NMDA receptors has a number of important consequences (see

Table 1). Because activation causes spinal neurons carrying pain to be stimulated with
less peripheral input (a phenomenon known as "windup"), less glutamate is required to
transmit the pain signal, and therefore significantly more anti-nociceptive input is

required to stop it [31 ]. Endorphins and other naturally occurring pain-relievers cannot

keep up with the demand and essentially lose their effectiveness. So do exogenous
opioids at usually prescribed dosages. The clinical implications are clear but
underappreciated--inadequately treated pain is a much more important cause of opioid
tolerance than use of opioids themselves.

Table 1. Results and Responses to NMDA receptor activation
Normal

Neuropathic

Wind-up

Injury Discharge

Inflammatory

Long-Term

Neuronal

Gene-Induction

Responses
Reduced Opioid
Effect

Hyperalgesia

Hyperalgesia

Allodynia

Reduced Opioid
Effect

Novel
Neurotransmission
Cell Death

(time dependent)
Reduced Opioid
Effect

Pain Memory

Reduced Opioid
Effect
Adapted from Brookhoff, 2000 and Dickerson, 1994.
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Healing
The biochemical basis of healing has not changed over the eons because it is an

efficient, complicated and magnificent process. Healing of injured tissue is complicated.

Once an animal is injured, multiple responses are induced and a symphony of cells,
proteins, cytokines, growth factors and neurohumoral factors begin the process of

healing. Interestingly, inflammation is necessary to induce healing and is the basic
physiologic process that is common to all wounds [33]. Once started, this process has
essentially three phases that overlap and share common mediators. One of the major

goals of healing is to lay a new foundation of connective tissue and allow the maturation
of this tissue into a well-formed network of linked proteins that have a solid matrix and
increased tensile strength. Regardless of the tissue involved, the same process occurs
with the resultant differentiation of tissue dependant upon the foundation to which it is

attached and the forces applied to it. There are four divisions of healing that are

generally described: Inflammation, Epithelialization, Fibroplasia and Maturation [34].

Often, epithelialization and fibroplasias are grouped into the "proliferative" phase since it
is during this period that epithelial cells and fibroblasts propagate. It is also during this

phase that the most important substance is produced, collagen (Figure 2).

In the inflammatory phase, vasoconstriction initially occurs for hemostasis and
platelets aggregate to the wound site. Mononuclear leukocytes begin to accumulate and
eventually differentiate into macrophages [35,36,37]. During this phase, mast cells
degranulate and release histamine, among other mediators, which causes edema and more
importantly, cellular migration. The resulting chemotaxis is driven by cytokines and

growth factors. Among them are the interleukines, interferons, tumor necrosis factor,
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platelet derived growth factor (PDGF), and transforming growth factors (TGF) [37].

PDGF released at the wound site appears to be the primary wound hormone and has both
chemotactic and mitogenic activity toward fibroblasts and smooth muscle cells [33].

Finally, small vessels become permeable to molecular and cellular mediators. Clinically,
this is identified by the accumulation of edema, swelling and pain [34]. Macrophages

peak at approximately three days, which coincides with the peak of the swelling and pain
that a patient will experience after wounding.
The proliferation phase begins approximately 4 days after wounding and actively

promotes healing for approximately 42 days. It is marked by the increase of three
specific cell lines and follows the peak of macrophage migration and differentiation.
Fibroblasts, epithelial cells and endothelial cells are the main players during this phase.
Fibroblasts are "summoned" to the wound in a multitude of ways but most importantly by
chemotactic and growth factors liberated by the macrophage and local cells. The wound
is less edematous at this point and the main activity is the deposition of collagen by

fibroblasts [33]. It is critical to allow the first two phases of wound healing to occur. To

decrease the pain people experience after injury and wounding, physicians often prescribe
medications (i.e. NSAIDs, steroids, even ice to some degree) that interfere with these
crucial stages thus interfering with the deposition of collagen. Because of its importance

in healing and thus pain, collagen, its structure, and biosynthesis will be discussed below.

The third stage of healing, maturation, begins about 3 weeks after wounding and
continues for upwards of three years (although the majority of maturation occurs by nine

months in adults) [33]. This phase is responsible for the maturation and remodeling of
connective tissue that is continually being laid down during the proliferation phase. The
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proliferation and maturation stages overlap dramatically. In fact, biochemically many of
the cytokines and growth factors overlap and induce responses in a variety of cells at any

given time during the healing of a wound [37].
The process by which collagen matures and stabilizes by intermolecular cross-

linking is called remodeling. It is also during this third phase of healing that wound
tensile strength increases dramatically and, if graphed, is represented by a sinusoid curve

that plateaus below the original tissue’s tensile strength [38]. It is important to realize
that the wound’s tensile strength is not solely due to collagen synthesis or its quantity. It

may be related to the type of collagen that is produced or to its final form [38]. For

example, during granulation of a skin wound, the collagen that is laid down resembles
type III collagen, which is characteristic of embryonic collagen. During maturation, this
type III collagen is replaced by type I, the usual collagen found in skin [38]. Thus,
maturation of the wound by intermolecular cross-linking helps to differemiate the

collagen matrix and increases the tensile strength of the wound [38]. Once inflammation
is induced, particularly at the ligaments or tendons (any connective tissue in theory), the

healing of the incompetent tissue ensues and eventually, through physiologic forces (see
"connective tissue" below) organizes into structurally normal, non-pathologic connective
tissue [39].
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Figure 2. Timing of Healing.
Relative amounts and timing of two key cells in healing with the resultant collagen
accumulation in time. Growth factors and cytokines specific for the cell are represented (not
in order of importance or relative concentrations) in the area under the curve.
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TNF-c=Tumor Necrosis Factor-alpha; TGF-t= Transforming Growth Factor-alpha; TGF-13= Transforming growth Factorbeta; IL 1-13 Interleukin-l-beta; HB-EGF=Heparin Binding-Epidermal Growth Factor; 13-FGF=beta-Fibroblast Growth
Factor; IGF-l=Insulin-like Growth Factor-I; PDGF=Platelet Derived Growth Factor; KGF=Keratinocyte Growth Factor
Adapted, in part, from Witte, et al. 1997, and a review of the literature.

Connective Tissue
Connective tissue is made up of macromolecules with collagen being the most

abundant. It is ubiquitous and can be found in most organs and tissues of the body [40].
These macromolecules are comprised of at least 19 different types of collagen, fibrous
proteins (elastin and fibrillin), and a series of proteoglycans. In recent years, researchers
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have found other molecules in this matrix but have only partially defined their roles in
connective tissue [40].

Collagen is the most abundant protein in the animal world and provides the very
structure to which all cells interact. As mentioned above there are many forms of

collagen, however, not all have known functions [38]. Type I is primarily found in skin

(80%), bone (90%), tendons and ligaments, and most organs. Type II is found in
cartilage (50%) and the vitreous humor of the eye. Type III is found in blood vessels, the
uterus and skin (10%) [38].

These first three types are known as the fibrillar or

interstitial collagens and can form tough dense structures. Types IV

XI are amorphous,

do not form fibrils, and are found in interstitial tissue and basement membranes

[38](Table 2). Fibril assembly is fascinating. The collagen that forms these fibrils is
long and rod-like owing to its triple helix conformation. The triple helical formation
occurs because of the molecular structure of the component three chains. Every third

amino acid is glycine, the smallest amino acid. This chain can be designated by the

formula (-gly-X-Y-)333 since each sequence is about 1000 amino acids long. When three
chains are near each other they form the triple helix since the glycine amino acid

sterically limits the potential binding spaces of the molecules. The remaining amino
acids (X and Y) are mainly proline and hydroxyproline, which add stability and strength
to the triple helix. These chains are bound to other chains spontaneously due to

hydrophobic and charged regions along the surface of the molecules, thus forming into

large collagen fibrils [40]. The self-assembly of the collagen fibrils takes place in the
extracellular space, in particular, at the sight of a wound or injury.

2O

Table 2. Major Types of Collagen

Type

Characteristics
Bundled fibers
High tensile strength

Distribution
Skin(90%), Bone,
Tendons, Ligaments

II

Thin fibrils, structural

Cartilage, vitreous
humor

III

Thin fibrils, pliable

Blood vessels, uterus,
skin (10%)

IV

Amorphous

All basement
membranes, basal

V

Amorphous/fine fibrils

lamina
Interstitial tissues
(2%-5%), blood
vessels

Function
Structure, strength,
integrity of tissue
Shock absorption,
joint mobility
Allows mobility and
distensibility of
vessels
Filtration, mess-like
scaffolding

Cytoskeleton of cells,
similar to type III

Fibroblasts are the producers of what will eventually become collagen matrix.

While in the fibroblast, the proc chain, procollagen, is more soluble and is synthesized by

ribosomes [40]. This chain comes off of the ribosome and moves into the rough

endoplasmic reticulum and undergoes biochemical modification. At this point it has an
extra length of polypeptides at either end of the chains

(these promote solubility) [38].

From here, the chains move to the golgi apparatus and are excreted from the cell while a
procollagen peptidase clips the polypeptides off of the procollagen molecule. This
extruded molecule is insoluble in the extracellular space and is now called collagen [41 ].

In the extracellular space the collagen begins to form fibrils, which in turn begin to line
up and form fibers. This process is called cross-link formation and is regulated by the
enzyme lysyl oxidase [41]. It is here that collagen gains its structural integrity and

strength. "On a per weight basis, the strength of collagen approaches the tensile strength
of steel!" [41]. As collagen begins its cross linking, it also looses water. It becomes a
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white semi-crystalline material that is firm, similar to the texture of ligaments and

tendons. As the water is displaced by protein-protein hydrogen bonds, the collagen takes
up less space and contracts [42].

Scar collagen, which fills the void left by trauma (intended as in surgery or

accidental), does not regain the same strength as the collagen of the original tissue

[33,38]. In fact, it may only achieve 70%-80% of the original strength [38,43]. After
injury, the body tries to reestablish highly organized tissue with normal strength through
an ongoing battle between the degradation and the production/remodeling of collagen.

There is an equilibrium that develops and anything that interferes with production,

remodeling, or maturation will offset the balance and shift the process toward
degradation [41 ]. If this happens, the wound becomes weak and unstable. Proper
nutrition and avoiding medications that inhibit the production of proteins become

important to proper healing and remodeling in time [41 ].

Structure and Function
Ligaments and Tendons are highly organized bundles of protein. The collagen in
ligaments is arranged in parallel, oblique, or spiral orientations as an adaptation to

specific forces and restrictions on joint mobility [44]. Tendons are bundles of collagen
fibers that connect muscle to bone and transmit tensile forces produced during muscle

activity through the enthesis (osseo-tendinous junction or fibro-osseous junction) to the
bone. These attachments vary in shape based on the muscle’s purpose [44]. This strong
attachment is accomplished by decussating and perforating Sharpey’s fibers and creates
an attachment that histologically has four zones: tendon zone, fibrocartilage zone,
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mineralized fibrocartilage zone, and lamellar bone [44,45]. Within this attachment there
is a high concentration of nociceptors and blood vessels, which perforate the transition

fibers from the tendon or ligament at the attachment of the bone. In fact, the tendons and

ligaments proper have relatively few nociceptors compared to their attachments at the
enthesis [27]. When injured, this is the area that inflammation and pain is produced and
is also the place where healing can occur.

Sources of Pain
Pain can originate from many structures and in many places but when it originates

from the musculoskeletal system specific lesions can often be identified. Pain generating
structures in the musculoskeletal system are fascia, ligaments, tendons (including their

muscles), enthesis, intervertebral discs and the joints [44]. Fascia is an interesting and
all-encompassing tissue that is critical for the normal physiologic function on the
musculoskeletal system and deserves some attention.
Fascia is connective tissue that is everywhere in the body. It covers, supports and
lubricates the organs and muscles [46].

"The fascia is the major connector between the ectodermal
derivatives of the outer body and the endodermal
derivatives of the inner body. It contains and maintains the
internal environment, the ECF, and orchestrates
homeostasis. No disease escapes notice in the fascia and
no cure occurs without its assistance.t" [47]

Since the fascia is so important to homeostasis, it would make sense that an alteration in

body mechanics and stresses on tissue would alter the healing process. It is known that
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tissue organizes and then re-organizes in response to the stresses placed upon it. An

example of this is Osgood-Schlatter disease and the remodeling of bone while under
stress. The transmission of forces through the fascia guides the repair process. "The

linear nature of the healing collagen is dictated by the distribution of fibrin matrix in

response to tension in the tendon" [44]. It becomes essential, therefore, to introduce
movement into traumatized tissue in order to establish the correct blue-print for matrix

formation, repair, and to re-establish normal physiology [44]. A formal review of fascia

and its essential role in homeostasis is beyond the scope of this article but it is prudent to
realize that including this connective tissue in the healing and repairative plan will greatly

increase the success of the treatments, and will also help to re-establish homeostasis.

The ligaments maintain stability of a joint and, when sprained due to sudden

shearing forces, generate pain due to disruption of the enthesis [44,48]. Tendons secure
muscle to bone and when this attachment is compromised (as in a strain) inflammation

and pain develops [44,49]. Enthesopathies develop due to poorly organized and

degenerated tissue at the enthesis (osseo-tendinous junction)[45,50]. Tendinosis and
ligamentosis (non-inflammatory conditions) are essentially a failure of cell matrix
adaptation due to excessive load and tissue hypoxia [44,50]. This wound is often
mistaken for tendonitis or ligamentitis and treated with anti-inflammatory medications

that fail since the requisite inflammation for these medications to work is not present

[50]. Ligament laxity, whether post-traumatic or congenital, often leads to painful
hypermobility [44,51]. It is this specific reason that may people, once injured, never fully
return to their pre-injury, pain status. Interestingly, this concept is not taught in medical

school. In fact, this is a new and developing field of musculoskeletal medicine that seeks
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to focus on the origin of the pain and not in the resultant sensation of the injury [45]. It

should be noted that the sensation of pain due to musculoskeletal injury is what brings

patients to see the doctor. This is addressed most often in the traditional ways...rest, ice,

compression and elevation (know as R.I.C.E. therapy) with or without a pain medication

(non-steroidal anti-inflammatory medications, narcotics, etc.). This acute phase of
treatment is often repeated over the course of the injury well into its chronic stages. It

has been shown in recent literature that treating the pain from these injuries, once they are

chronic, by focusing on the inflammation is not effective [26] and, as was demonstrated

above, by stopping inflammation there is the risk that the injury might not heal
completely.

As has already been discussed, a major driving force, which prevents physicians
from treating a patient’s pain more aggressively and appropriately, is the inadequate use
and fear of prescribing narcotics.

Chapter 3
How Pain Affects Us
Interpretation of Pain
The human body makes its own pain medication. These chemicals block pain by

inhibiting the transmission of pain through the spine and also by blocking the activation
of the "pain" receptors in the brain. Injuries in the body trigger a complex and

fascinating cascade of events that translates into the perception of pain. The signal that
initiates the cascade is inflammation due to the tissue damage of the injury. The

inflammatory mediators and growth factors (see Table 3) trigger pain signals that
transmit an impulse electrically to the brain via unmylinated nerve fibers (C-fibers) called

nociceptors. These C-fibers synapse in the dorsal horn of the spinal cord with the
spinothalamic tract to carry information to the cerebral cortex. It is here, in the cerebral
cortex, that pain is perceived, interpreted, and localized. It is here, in the central nervous

system, that narcotic based medications work.

Table 3. Growth Factors in Inflammation
PDGF

Platelet derived growth factor

TGF-J3

Transforming growth factor-[

TGF-c

Transforming growth factor-

FGF

Fibroblast growth factor (acidic, basic)

KGF

Keratinocyte growth factors

EGF

Epidermal growth factor

IGF-1

Insulin-like growth factor-1

VEGF

Vascular Endothelial Growth Factor
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The Anti-Pain System

Often not thought of, but equally as important is the anti-nociceptive system that

allows us to function even though we are in pain. Once pain signals arrive in the brain,

they stimulate the release of endorphins in the periaquiductal gray matter and enkephalins
in the nucleus raphe magnus of the brainstem. Endorphins inhibit the propagation of pain

signals by binding the Mu-receptors on the post-synaptic terminals of the nociceptors and
also post-synaptically on the dorsal horn. The enkephalins bind to delta-receptors on

inhibitory interneurons in the substatia gelatinosa of the dorsal horn. This in turn causes
a release of gamma-aminobutyric acid

(GABA), among other chemicals, that moderate

the flow of pain signals in the dorsal horn [32]. Dynorphins are chemicals released by
the spinal interneurons, which activate kappa-opioid receptors. These activated receptors
lead to closure of the N-type calcium channels in the spinal cord cells that normally relay
the pain signals to the brain [32]. This complex mechanisms to counter the sensation of

pain is absolutely necessary to human survival. Imagine a minor injury, such as a paper
cut or scraped knee, that never stops hurting, eventually leading to total disability. The

human race would not have survived.

Pain Begets Pain

Once the pain cascade is initiated, the pain sensing system becomes more
sensitive; thus it is easier to start and maintain the painful sensations. Enkephalins are

produced when nociceptors are active. While these nerves are transmitting pain, the
enkephalins bind to the presynaptic delta-receptors, which are found on vesicles

containing neurotransmitters. Once the neurotransmitters are released, the delta receptors
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are incorporated into the presynaptic cell membrane and augment the pain transmitting

ability and efficiency of the nociceptive fibers [32].
The physiology of chronic pain is not a variation of acute pain. There is a

physiochemical change that makes the neural pathway hypersensitive to painful
stimulation and resistant to anti-nociceptive input. When thought about in these terms,

there are two possible pathways to chronic pain. The first is a direct route, which
essentially stimulates the pain sensing fibers and does not cease, thus overwhelming the
pain sensing areas of the brain. The second way is to alter or impair the anti-nociceptive

system in such a way as to decrease or inhibit its ability to function normally. It is this
latter theory that is currently being explored in the pathophysiology of fibromyalgia

[9,32].

Chapter 4
Barriers to Treatment
Medication Barriers

The above physiology and neurology review sets the stage for physicians and the

perceived barriers inhibiting the treatment of chronic pain. It is believed in medicine that
patients with chronic pain always keep coming back and never get better. In the past, the
science of pain was poorly understood and this comment developed as a result of the lack

of treatment options except for opioids. Opioids have been available for physicians to

prescribe to their patients as early as 3400 BC in lower Mesopotamia. First cultivated
from Papaver Somniferum (the opium poppy), opium was used for centuries to treat
many illnesses and diseases. The Sumerians referred to it as "Hul Gil" (or "joy plant") in
3000 BC. In 460 BC Hippocrates acknowledged opium’s use as a narcotic and styptic in

treating internal diseases, diseases of women and epidemics, essentially for its awesome

pain relieving properties [52]. Since then, opium and its derivatives have seen many uses
and mis-uses, both medicinally and recreationally. It is the extraordinary history of the

opioid medications that contributes to their cautious use by physicians.

Despite good intentions and genuine concern for patients’ comfort on the part of
physicians, research on pain therapy over the past 20 years suggest that many patients do
not receive adequate pain relief. In 1973, Marks and Sachar documented the under-

treatment of pain in hospitalized medical in-patients and since this time, these findings

have remained consistent [53,54]. Interestingly though, according to pain experts, 70%

90% of people in acute or chronic pain could have adequate relief with the use of nonsteroidal anti-inflammatory and narcotic medications [55]. There are common
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misconceptions about treating pain with narcotics that need modification. The most
common misconception is wrapped around a concept known as addiction.

Terminology Barriers
Addiction is a compulsive disorder in which an individual becomes preoccupied
with obtaining and using a substance. Continued use of the substance could result in a

decreased quality of life. Addiction can also be described as a primary, chronic,

neurobiologic disease. There are genetic, psychosocial, and environmental factors

influencing its development and manifestations. It is characterized by behaviors that
include the following: impaired comrol over drug use, craving, compulsive use, and
continued use despite harm. Physical dependence and tolerance are normal physiological

consequences of extended narcotic therapy for pain and are not the same as addiction

Tolerance is the development of a reduced effect of a narcotic with continued,
chronic use. This is a physiologic state resulting from regular use of a drug and leads to

the need to increase dosage to produce the desired pain relieving effect. Tolerance may
or may not be evident during opioid treatment and does not equate with addiction

[56].

Dependence is a physical state that develops with long-term use of narcotics.
This is an adaptation of human physiology manifesting itself when the dose of a narcotic

is rapidly reduced or stopped abruptly. This "withdrawal" is not addiction, but a very

real physical dependence upon the medication [30].
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Access Barriers
Access to professional services, prescription drugs, and medical equipment is
usually necessary for effective pain care [57]. The lack of reimbursement influences the
way in which pain is treated, where it is treated, and the necessary supportive care that is
available [58]. Interestingly, for those who are insured, reimbursement policies may

favor the use of more expensive pain management modalities over less expensive ones.
Medicare, for example, does not reimburse for outpatient oral medications (including

narcotics) but will reimburse for pain management in an inpatient facility. Thus, "a
person may well have reimbursement for the $4,000.00 cost of patient controlled

analgesia (PCA) morphine but will have no coverage for $100.00 of oral morphine
solution" [59]. Clinicians should consider a patient’s ability to pay for treatmem. The
cost of medications and other treatments may overburden a patient with limited financial

resources and result in compromises between compliance with the prescribed regimen

and other financial responsibilities [60]. Costs of analgesic drugs, for example, including

many that are equally effective for pain management, vary dramatically [61 ].

Chapter 5
Public Health v. Public Safety
The Opium Concern
"...when diverted from the legitimate distribution system, the non-medical use of
controlled substances can lead to serious public health problems..." [62].

As already mentioned, opium and its derivatives, also known as opiates, have
been used for centuries to relieve pain and suffering. Because of their addictive potential,

opiates have been the focus of law enforcement agencies for decades. In fact, opium and
its derivatives were the focus of the first conference for drug control held in Shanghai in

1909. This conference, known as the Opium Commission Forum, was attended by 13
countries. Its purpose was to establish guidelines for controlling the growing opium

market. Escalating addiction problems in Far Eastern countries and the rapid

development of the opium trade led to the first Drug Control Treaty signed in The Hague
in 1912. The focus of this treaty was to simply limit the manufacture and trade of opium

for solely medical purposes [63].
During the International Opium Convention of 1925, a statistical system of

monitoring the production, manufacture, trade, and distribution of opioid drugs was

developed with a Central board to oversee its activity. By the 1931 gathering of this
convention, the participating governments were required to supply annual estimates of
their opiate needs and their potential production based specifically on, and limited to,

medical and scientific need [63].

Why do physician’s under-prescribe opiates and controlled substances? This
question has multiple answers, but boils down to this" Are physicians under-prescribing

31

32

because of lack of knowledge or fear of regulatory oversight? Could both factors be the

case?

In every modem country there is a need to protect the public from harm. Laws

develop in countries to police, regulate and defend its citizens. In the United States,
particularly focused on public health, a three-tiered foundation for our modem drug laws

developed from international treaties, federal laws and state laws. The primary goal of
these laws is to balance appropriate medical use of controlled substances with the illicit
diversion of these drugs [62].

International Treaties

Internationally, the principal treaties recognize that many controlled substances
are indispensable to public health and that their availability for legitimate medical and

scientific purposes must be ensured [64,65]. Most governments of the world agree with

these treaties [66]. In some countries, laws have become so strict, that judicial,

appropriate use of opioid medications is curtailed and in some cases restricted due to the

laws that developed to protect against diversion [67].

Federal Laws
The Federal laws in the United States adequately balance diversion and

appropriate medical use. The Federal Food, Drug, and Cosmetic Act of 1962 gave the
Food and Drug Administration (FDA) the power to approved opioids, stimulants, and
sedative hypnotic as safe and effective for medical use and commercial marketing. This
act did not restrict physicians from prescribing medications to either labeled indications
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or recommended doses

[68]. In fact, "...a physician may prescribe it (medication) for

uses, in treatment regimens, or in patient populations that are not included in the

approved labeling" [69]. The federal anti-drug efforts developed to allow physicians to
still have control over treating their patients. "Appropriate medical practice and patient

interest require that physicians be free to administer drugs according to their best

knowledge and judgment" [70].

"New uses for drugs are often discovered reported in
medical journals and at medical meetings, and

subsequently may be widely used by the medical
profession When physicians go beyond the directions
given in the package insert it does not mean they are acting
illegally or unethically, and Congress does not intend to
empower the FDA to interfere with medical practice by
limiting the ability ofphysicians to prescribe according to
their best judgment" [71].

In summary, when physician go beyond the packet insert, they are not acting
illegally or unethically and Congress will not interfere with the practice of medicine. The
practice of medicine is deferred to the states as long as the state laws do not conflict with

federal law [71 ].

Controlled Substances Act
The Controlled Substances Act (CSA) of 1970 parallels International treaties in

that it attempts to balance illicit diversion with appropriate medical use. The CSA

specifically states that legitimate medical use is "...necessary to maintain the health and

general welfare of the American People" [72]. It is the CSA that allows for the
scheduling of medications based on their abuse potential. The scheduling of medications
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is an attempt to monitor medication production and prescribing habits of physicians.
Medications are categorized in any one of five schedules (categories). Schedule II
medications have the highest potential for abuse while schedule V medications have the

least. Schedule I medications are reserved for research and scientific purposes only.
Worried that excessive production of controlled substances would increase diversion and
illicit use, the CSA gave authority to set production quotas for many of the opioids,

sedative hypnotics and stimulants to the Drug Enforcement Agency (DEA). These

quotas must accommodate legitimate medical and scientific needs [72].

Uniformed Comrolled Substances Act and State Law

The states regulate medical practice, not the federal government. This authority is
based on the police power in state constitutions and it underlies the medical practice acts
that are designed to protect the public health and safety [73].
The state laws, like the federal laws, prohibit the non-medical use of controlled
substances. However, state laws do not clearly recognize the public health benefit of

controlled substances or the need to balance their availability for medical purposes. In

fact, most state laws imerfere with the prescribing of comrolled substances [62]. The
model for most state laws is the Uniformed Controlled Substances Act (UCSA) of 1970.
This is a federally influenced act to help unify the out-dated and often oppressive older
state laws and to help the states achieve a more appropriate balance between licit and
illicit controlled substance use. Instead, the UCSA simply mentioned that states could

include an advisory committee to oversee the state regulatory agencies. In addition, there
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is no mention of ensuring availability of medication for professional use nor is there a

definition of "addict," thus leaving the individual states to define this.

Federally, an addict is one who is a danger to society and to whom narcotics can
only be prescribed by specially registered treatment programs. A physician may not
prescribe opioids to an addict unless they are for pain. Once the states were allowed to
define addict, many confused addict with patients who are dependent on narcotics (see

above), thus limiting (not eliminating) the physicians’ ability to prescribe opioid
medications to those in pain [74]. Although many states adopted the UCSA, many did
not repeal their existing laws, thus creating (in many cases) a combination of antiquated

laws with new, confusing laws that influence the prescribing and manufacturing of
controlled substances.

Multiple Copy Prescription Program

Although controlled substance prescriptions and manufacture are monitored, one

state’ s novel program, implemented in 1913 in New York, directly affects a physician’ s
ability to prescribe controlled substances. The multiple copy prescription program

(MCPP), or "triplicates," was developed specifically to monitor the prescribing and
dispensing of narcotics. Since this time, 16 additional states have developed monitoring
programs (whether "triplicate" or "duplicate" prescriptions or electronic) (see Table 4).
The DEA believes the MCPP is one of the best ways to control opioid diversion. With its

implementation, Schedule II prescriptions generally decrease by 50%, the states

consumption of controlled substances decreases and there is a decrease in the number of
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Table 4. States Currently Monitoring Controlled Substanc
Prescriptions

Program

Year Enacted

Schedules Covered

1940

Schedule II

1943

Schedule II and
Hydrocodone

1967

Schedules II, III, IV

1961
1995
1998
1992

Schedule II
Schedules II
Schedules II, III, IV
Schedule II

1989

Schedule II

Nevada
New Mexico

Triplicate /
Electronic
Duplicate /
Electronic
Duplicate /
Electronic
Triplicate
Electronic
E lect ro n ic
Electronic
Single Copy /
Electronic
Electronic
Electronic

1997
1994

New York

Triplicate

1913-15, 1972

Oklahoma

Electronic

1990

Rhode Island

Electronic

1979

Schedule II, III, IV
Schedule II
Schedule II and
Benzodiazepines
Schedule II
Schedule II, III, Needles
and Syringes

Texas

Triplicate /
Electronic
Electronic
Triplicate
Electronic

1985

Schedule II

1995
1989
1995

Schedules II, III, IV, V

State
California

Hawaii

Idaho
Illinois
Indiana

Ken tu cky
Massachusetts
Michigan

Utah
Washington
West Virginia

N/A-Punitive

Schedule II

physician requests for triplicate forms [75]. Studies have suggested that for physicians
who treat cancer pain, these decreases are largely due to a reluctance to prescribe

secondary to excessive state monitoring of Schedule II prescriptions [76]. The MCPP

programs can, in fact, preferentially influence the use of weaker opiates in terminally ill
patients when stronger medications would be appropriate [77].
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The current playing field for treating chronic pain with controlled substances is

fraught with obstacles. Although the regulation of medical practice is the states’
responsibility, international, federal and state laws are at play when controlled substances
are prescribed. Although there are no consistent or unified laws from state to state, there

is evidence that too much monitoring of the prescribing habits of physicians directly

influences patient care. Ultimately, the quest for appropriate balance between protecting

public health by limiting diversion of controlled substances and preserving the
physician’ s ability to treat patients remains elusive. As our understanding of the biology
of pain increases so does public demand for improved pain treatment. Perhaps, with

appropriate education and more unified state laws, this elusive balance can be attained.

Chapter 6
Education
Medical Schools and Physician Training

When faced with a patient in pain, most physicians will under-prescribe narcotic
medications either because they lack knowledge about how to use them or because they
are afraid to use them [78]. Physicians generally have not been taught in their medical

schools or residencies the specifics and subtleties of pain medicine. It was recognized in
1985 that medical schools were sorely lacking education on pain control, and the
International Association for the Study of Pain developed a model curriculum for medical

schools they believed would better prepare student physicians for treating this pandemic

problem [79]. Interestingly, this curriculum is still appropriate today even when
scientific advances are factored into the education; however, it is not being used in
medical schools [80]. Currently, in the United States, there are no medical schools that

have incorporated a specific curriculum on pain. Little is being taught about pain or pain

management, and information about pain is poorly integrated into the 4-year curriculum

[81 ]. When polled, practicing physicians state they had poor and inadequate training in
pain medicine [82]. In Canada, medical schools devote an average of 11 hours of
instruction to palliative care and cancer pain control [83,84]. A survey of 106 medical

studems completing a third-year clerkship in Arizona suggests that 57 (54%) felt they
were poorly equipped to deal with terminally ill patients with regards to their pain and

palliative care issues; upon graduation form medical school [85]. Medical education can

actually foster the mistreatment of pain because the lack of knowledge and the
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preconceived notions about pain and the negative opinions about pain medications impair
prescribing [86].

Resident Physicians
Since there is very little taught about pain in medical school, most resident

physicians are ill prepared for the appropriate treatment of pain. Most patients are treated
for acute pain in the hospital setting. Too often though, long-term treatment of chronic

pain is sorely lacking, usually due to the fear of addicting a patient. It has been estimated
that less than one percent of patients who are started on narcotics in the hospital during an
acute stay will become addicted

[87]. Opiophobia is a term that is used to describe a

well-documented medical syndrome that is fed by fear, superstition, and the war on drugs

[87]. Physicians in training are particularly susceptible to opiophobia because they often
do not have role models in the medical system that can appropriately educate them.
When doctors suffer from opiophobia, patients suffer from pain.

A Model Curriculum:
A pain curriculum must include some basic components. Medical students,
residents and attending physicians must be able to recognize pain, define its impact on

the patient, understand the normal pain transmitting physiology and the pathophysiology

of chronic pain. A curriculum should also prepare the students to be able to develop a

plan to treat the pain. Finally, this curriculum must also teach the students how to help a
patient maintain dignity during and throughout the treatment of their pain. In order to
accomplish these goals the institution utilizing an educational curriculum must be
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prepared to "practice what it preaches." This would require physicians to learn and
practice pain medicine. Often, patients in pain need psychosocial, economic and spiritual
assistance as well as physical and medical treatment. These components of management
are often the most difficult to orchestrate and can be the aspects of medical care that

create obstacles for the development of a pain medicine program (see "Barriers to Care"

above).
A chronic pain curriculum should educate the students in many different areas of
medicine. The interconnection of the physical, psychological, social and spiritual aspects

of a person is never more pronounced than when he or she is in pain. Therefore, a pain
curriculum should incorporate all of these components. The outline below presents a

sample chronic pain curriculum:

Outline of Chronic Pain CurriculumIntroduction
Pain as public health issue

Epidemiology of pain
Impact of pain on society
Economic impact of pain
Definitions
Acute vs. Chronic pain
Pain terminology
Basic Science

Neuroanatomy
Normal pain physiology
Pathophysiology of chronic pain
Anthropologic basis of pain
Clinical Science
Current evaluation tools
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Clinical Presentation
Patients and their varied presentations of pain

Ethical and medico-legal Issues
Physician’s obligation to treat
Impact on Healthcare system

Use of opioids
The "Controlled Substance Contract"
Balance appropriate use with diversion
Pain research in humans

Disability determination
Pain and opiate dependence

Management
Goals of treatment
Appropriate and realistic
Patient centered NOT physician centered
Expectations of medication treatment
Special chronic pain circumstances
Cancer pain
Neuropathic pain
Psychological (idiopathic) pain

Treatment
What’s available
Pharmacologic
Opioids
Adjuctive treatment
Complimentary therapies
Neuroleptics
Antidepressants
NSAIDs
Future trends

Chapter 7
Conclusion
The United States has a growing epidemic that began in amiquity. Pain, in its

purest form, is most probably the strongest survival sensation higher order animals have

developed. Acute pain is necessary for survival but chronic pain, to date, has not been
shown to have any survival advantage.

There are physiologic changes in the pain sensing system that develop with

prolonged (or intense) acute pain. These neuroanatomical transformations make the
transmission of pain easier and more efficient, thus fewer stimuli are needed to create

pain [31,32]. Why is this change in sensation needed when pain is chronic? How can
this be reversed? Medical science has not been able to answer these questions, but as

research on pain progresses, so needs the education of physicians to progress. Education
on pain and its management is lacking in medical schools. This deficit has been

recognized for many years, yet no formal programs have been added to the curricula of
any medical school [79]. Residencies have suffered the consequences of this lack of
education. Many of the preconceived biases concerning narcotics influence the practice

of medicine and add barriers to the treatment of pain. The attending physicians who
teach residents and students tend to under treat pain in the hospital. Possible reasons for
this include lack of experience with opioid medications, fears of side effects, medicolegal

issues, and the inability of physicians to heal the underlying chronic disease [87].
Disease management and the ability to care for all aspects of health is a popular

and proven method of managing chronic diseases. Chronic pain becomes an entity unto
itself and should be treated as a chronic, self-sustaining and progressive disease.
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Everyone has a right to be healthy. Generally, health care providers believe this to be
true. Although human rights may differ from legal rights, it is generally accepted that if a

person wished to be healthy, society will accept this and every effort should be made to

help a person attain health. This dictum, however, is not followed when chronic pain is
the cause of ill health.
The public health issues surrounding chronic pain are vast and reach many aspects
of society. The state and federal governments have a duty to protect public safety. But at

what cost? The regulatory agencies that are sworn to protect the public often develop
barriers to patient care that restrict and often inhibit the treatment of patients with
narcotics. The media reports the addiction of public figures partially for sensationalism,
which primes the lay-person with mis-information about the medications that might be

the most appropriate to treat their pain.
This paper reviewed the issues I believe are most important in reforming the

inadequate treatment of chronic pain in the United States. The cost of chronic pain to
society is awesome and is driven by inadequate management of its symptoms and its
altered physiology. The misconception that chronic pain should be treated like acute pain
is fostered by the lack of education of our young physicians in training and the fears of

prosecution by our more experienced physician trainers. These fears are based in laws
and regulations that attempt to balance diversion and illicit use with appropriate, licit
medical application. Most of the states that have monitoring programs for the prescribing

of controlled substances also have physicians who feel these programs are restricting
them from treating chronic pain appropriately. Understanding the pathophysiology of
chronic pain can allay much of the physicians fear and worry about prescribing comrolled
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medications. Recent research focusing on specific pathophysiologic changes that occur

when pain is not controlled, is increasing our knowledge base and will also aid in the

development of new medications targeting these changes. Educating student physicians
in medical school with specific curricula designed to incorporate the current pertinent
scientific literature into the issues surrounding pain treatment will be the most effective

way to ensure adequate pain treatment.
The medical understanding of chronic pain is growing as we look deeper into the

physiology and chemistry of man. Identifying the mechanisms that fuel disease can take
the mysticism out of the diagnosis and treatment of poorly defined illness. Although
chronic pain has been a chronic disease for as long as humans have roamed the earth, the
source of its mysterious natural history and unrelenting tenacity remains hidden. This

creates obstacles that prevent physicians from learning about pain and treating patients

appropriately.
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